The treatment landscape for inflammatory bowel disease (IBD) has entered an exciting new era of precision medicine, as innovative therapies such as interleukin-23 (IL-23) inhibitors offer renewed hope for sustained remission and improved quality of life. Rapidly emerging clinical trial …
The treatment landscape for inflammatory bowel disease (IBD) has entered an exciting new era of precision medicine, as innovative therapies such as interleukin-23 (IL-23) inhibitors offer renewed hope for sustained remission and improved quality of life. Rapidly emerging clinical trial …
Cardiovascular-kidney-metabolic (CKM) syndrome represents a progressive, interconnected continuum in which type 2 diabetes, chronic kidney disease, heart failure, and overlapping cardiometabolic risk factors mutually accelerate one another’s progression. In everyday family medicine practice, however, these conditions are often managed in …
The idiopathic inflammatory myopathy (IIM) landscape is evolving rapidly, transforming how clinicians recognize disease, assess risk, and select treatment, but translating these advances into everyday practice remains a challenge. As biomarkers and myositis-specific autoantibodies enable increasingly precise subtype classification, clinicians …
Although advances in antiretroviral therapy (ART) have transformed human immunodeficiency virus (HIV) into a manageable chronic condition, important gaps persist in the consistent, equitable application of care across diverse populations and global settings. Rapid innovation—including long-acting injectable (LAI) and multi-mechanism …
Despite significant advances in human immunodeficiency virus (HIV) care, there are persistent gaps in translating clinical trial evidence into real-world practice, limiting optimal outcomes. Clinicians must keep pace with a rapidly evolving treatment landscape—including antiretroviral therapy (ART) such as long-acting …
While treatment innovations have significantly improved outcomes for individuals with human immunodeficiency virus (HIV), gaps persist in the consistent delivery of equitable, guideline-concordant care, particularly among diverse and underserved populations. Optimal use of therapies, including long-acting injectables (LAIs), is restricted …
Despite major advances in human immunodeficiency virus (HIV) management—including effective antiretroviral therapy (ART) and long-acting injectables—gaps in screening, testing, and diagnosis continue to limit patient outcomes and prevention efforts. Many clinicians, particularly in primary care and community settings, face challenges …
Obesity is transforming the landscape of inflammatory bowel disease (IBD), shaping disease activity, treatment response, and long-term prognosis. As evidence reveals the impact of excess weight on biologic and JAK inhibitor effectiveness, emerging anti-obesity therapies, including GLP-1 receptor agonists, are …